Deciphera Pharmaceuticals Inc (DCPH) Expected to Post Q3 2018 Earnings of ($0.64) Per Share

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) – Research analysts at Leerink Swann issued their Q3 2018 earnings per share estimates for shares of Deciphera Pharmaceuticals in a report issued on Monday, September 24th. Leerink Swann analyst A. Berens forecasts that the company will earn ($0.64) per share for the quarter. Leerink Swann currently has a “Underperform” rating and a $28.00 target price on the stock. Leerink Swann also issued estimates for Deciphera Pharmaceuticals’ Q4 2018 earnings at ($0.75) EPS, FY2018 earnings at ($2.70) EPS, FY2019 earnings at ($2.50) EPS, FY2020 earnings at ($3.27) EPS, FY2021 earnings at ($3.08) EPS and FY2022 earnings at ($2.39) EPS.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity set a $55.00 target price on Deciphera Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 13th. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Tuesday, July 24th. SunTrust Banks started coverage on Deciphera Pharmaceuticals in a research report on Thursday, July 5th. They issued a “buy” rating on the stock. BidaskClub upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 3rd. Finally, Cantor Fitzgerald started coverage on Deciphera Pharmaceuticals in a research report on Thursday, September 6th. They issued a “buy” rating and a $53.00 target price on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. Deciphera Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $48.09.

Shares of Deciphera Pharmaceuticals stock opened at $38.50 on Thursday. Deciphera Pharmaceuticals has a 52 week low of $15.15 and a 52 week high of $45.61. The company has a current ratio of 18.44, a quick ratio of 18.44 and a debt-to-equity ratio of 0.05.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03.

Several large investors have recently bought and sold shares of DCPH. SG Americas Securities LLC purchased a new stake in shares of Deciphera Pharmaceuticals in the first quarter worth about $152,000. Schwab Charles Investment Management Inc. increased its stake in Deciphera Pharmaceuticals by 20.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 33,791 shares of the company’s stock worth $678,000 after acquiring an additional 5,737 shares during the last quarter. Northern Trust Corp increased its stake in Deciphera Pharmaceuticals by 12.8% during the first quarter. Northern Trust Corp now owns 84,732 shares of the company’s stock worth $1,698,000 after acquiring an additional 9,640 shares during the last quarter. BlackRock Inc. increased its stake in Deciphera Pharmaceuticals by 37.5% during the first quarter. BlackRock Inc. now owns 499,879 shares of the company’s stock worth $10,018,000 after acquiring an additional 136,396 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Deciphera Pharmaceuticals by 64.3% during the first quarter. JPMorgan Chase & Co. now owns 287,762 shares of the company’s stock worth $5,767,000 after acquiring an additional 112,581 shares during the last quarter. Institutional investors own 53.53% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Recommended Story: What are the reasons investors use put options?

Earnings History and Estimates for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply